Monthly Archives: June 2007

Risky Business

Posted on June 13, 2007 by Mark Senak

Last week, the FDA announced the formation of a new Risk Communications Advisory Committee that will differ from the existing Drug Safety and Risk Management Advisory Committee, presumably by focusing solely on communication of risk. Yesterday and today, the FDA … Continue reading →

Posted in Risk Management | Comments Off on Risky Business

New Media and Pharma – An Intermittent Series

Posted on June 12, 2007 by Mark Senak

Sorry there was not Weekly Roundup on Friday.  A bus caught fire in my neighborhood and knocked out my Internet access.   Go figure.  Today’s posting is part of a series I’ve begun based on my belief that pharmaceutical companies are … Continue reading →

Posted in Marketing | 3 Comments

Alzheimer’s = An Insidious Disease State (AIDS)

Posted on June 11, 2007 by Mark Senak

In the Sunday New York Times Business Section, there was an article about Alzheimer’s research.  As I read it, I was struck by the current state of research and the way it mimicked the AIDS epidemic during the late 1980s.  … Continue reading →

Posted in Research | 4 Comments

The Congressional Hearing on Avandia

Posted on June 7, 2007 by Mark Senak

I attended the House Committee on Government Oversight and Government Reform hearing on the GlaxoSmithKline diabetes drug Avandia yesterday.  It was crowded and heated, both literally and figuratively.  If you are interested in watching the video of the Avandia hearing, … Continue reading →

Posted in Drug Safety | Comments Off on The Congressional Hearing on Avandia

Risk Management Committee Announced; Congressional Hearing Tomorrow

Posted on June 5, 2007 by Mark Senak

Yesterday the FDA announced the formation of the Risk Communication Advisory Committee – a new 15 member committee solely dedicated to help FDA better understand the communication needs and priorities of the general public; advise FDA on the development of … Continue reading →

Posted in Drug Safety | 5 Comments